A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Jun 2017 Results (n=105 as of 16 Dec 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2015 Planned number of patients changed from 102 to 105, according to ClinicalTrials.gov record.